CLINICAL TRIALS PROFILE FOR TERCONAZOLE

All Clinical Trials for terconazole

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00803738 ↗	Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis	Completed	Padagis LLC	N/A	2002-12-01	The objectives of this study were to demonstrate comparable safety and efficacy of Terconazole Vaginal Suppositories, 80 mg(Test Product) and Terconazole Vaginal Suppositories, 80 mg(Reference Product) in the treatment of subjects with vulvovaginal candidiasis in order to establish bioequivalence.
NCT00803738 ↗	Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis	Completed	Perrigo Company	N/A	2002-12-01	The objectives of this study were to demonstrate comparable safety and efficacy of Terconazole Vaginal Suppositories, 80 mg(Test Product) and Terconazole Vaginal Suppositories, 80 mg(Reference Product) in the treatment of subjects with vulvovaginal candidiasis in order to establish bioequivalence.
NCT01867164 ↗	A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vagin	Completed	Janssen-Cilag, S.A.	Phase 3	2007-12-01	The purpose of this comparative study is to evaluate the efficacy of an ovule with triple active agents (terconazole, clindamycin and fluocinolone) versus another ovule with triple active agents (nystatin, metronidazole and fluocinolone) in the treatment of symptoms caused by the presence of vaginitis (inflammation of the vagina) or bacterial vaginosis (polymicrobial, nonspecific vaginitis associated with positive cultures of Gardnerella vaginalis and other anaerobic organisms and a decrease in lactobacilli).
NCT02180100 ↗	Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis	Completed	Shanghai Shyndec Pharmaceutical Co., Ltd.	Phase 4	2013-08-01	The objectives of this study were to demonstrate comparable safety and efficacy of Terconazole Vaginal Suppositories, 80 mg and fluconazole in the treatment of subjects with severe vulvovaginal candidiasis.

Clinical Trial Conditions for terconazole

Condition Name

Condition Name for terconazole
Intervention	Trials
Vaginal Infection	3
Vulvovaginal Candidiasis	3
Infectious Vaginosis	1
Vaginal Candidiasis	1

Condition MeSH

Condition MeSH for terconazole
Intervention	Trials
Candidiasis, Vulvovaginal	4
Candidiasis	4
Infections	4
Infection	4

Clinical Trial Locations for terconazole

Trials by Country

Trials by Country for terconazole
Location	Trials
United States	72
China	1
Mexico	1

Trials by US State

Trials by US State for terconazole
Location	Trials
Nevada	3
Nebraska	3
Missouri	3
Michigan	3
Illinois	3

Clinical Trial Progress for terconazole

Clinical Trial Phase

Clinical Trial Phase for terconazole
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	5
N/A	2

Clinical Trial Status

Clinical Trial Status for terconazole
Clinical Trial Phase	Trials
Completed	6
Not yet recruiting	1
Unknown status	1

Clinical Trial Sponsors for terconazole

Sponsor Name

Sponsor Name for terconazole
Sponsor	Trials
Curatek Pharmaceuticals, LLC	3
Assiut University	1
Hatem AbuHashim	1

Sponsor Type

Sponsor Type for terconazole
Sponsor	Trials
Industry	8
Other	3